KEYNOTE-183 trial of pembrolizumab in multiple myeloma: trial design and rationale
Upcoming trials for DLBCL: R-CHOP with acalabrutinib and obinutuzumab with checkpoint inhibitor
How the removal of macrophages from tissue can stop or slow down the progression of CLL
Panel discussion on new technologies in lymphoma - the applications of circulating tumor DNA
Ash Alizadeh et al.
Overcoming the challenges of evolving standards of care in CLL: advice for community physicians